Clinical Trial Update: Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study [Phase 3]

View source ↗

Summary

A Phase 3 China-extension trial comparing pembrolizumab plus lenvatinib versus chemotherapy in endometrial cancer has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Lenvatinib (Lenvima) (lenvatinib)
• Pembrolizumab (Keytruda) (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Endometrial Neoplasms | Phase 3 | Status: COMPLETED | Results posted: 2024-10-18